Evaluation of T- and NK-Cell-Targeted therapies: Is there a role for rituximab prophylaxis?

Research output: Contribution to journalShort survey

Abstract

Splizimomab, an antibody that targets CD2, was studied in the treatment of Tand natural killer cell lymphoma and was found to be associated with Epstein-Barr virus lymphoproliferative disease. B cell depletion may provide a platform for further evaluation of this and other promising antibody approaches that result in T cell depletion.

Original languageEnglish (US)
Pages (from-to)2205-2206
Number of pages2
JournalClinical Cancer Research
Volume15
Issue number7
DOIs
StatePublished - Apr 1 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Evaluation of T- and NK-Cell-Targeted therapies: Is there a role for rituximab prophylaxis?'. Together they form a unique fingerprint.

  • Cite this